Ashwani Verma Analyst PerformanceAnalyst at UBS GroupAshwani Verma is a stock analyst at UBS Group in the healthcare sector, covering 25 publicly traded companies. Over the past year, Ashwani Verma has issued 69 stock ratings, including strong buy, buy, and hold recommendations. While full access to Ashwani Verma's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Ashwani Verma's coverage history, rating activity, and performance tendencies - helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings92 Last 1 YearsBuy Recommendations68.54% 61 Buy RatingsCompanies Covered25 Unique Companies Ratings Distribution89RatingsDistribution of strong buy, buy, hold, and sell ratings by Ashwani Verma.RatingPercentageCount Strong Buy1.1%1 ratings Buy67.4%60 ratings Hold31.5%28 ratings Sell0.0%0 ratingsOut of 89 total stock ratings issued by Ashwani Verma at UBS Group, the majority (67.4%) have been Buy recommendations, followed by 31.5% Hold and 1.1% Strong Buy.Best & Worst CallsBest Call0000.0%AVDLJan 2025Subscribe to MarketBeat All Access to get analyst recommendation ROI.Worst Call000.0%LEGNJul 2025Subscribe to MarketBeat All Access to get analyst recommendation ROI.Exchange CoverageExchangePercentageCountNASDAQ88.0% of companies on NASDAQ22 companiesNYSE12.0% of companies on NYSE3 companiesAshwani Verma, an analyst at UBS Group, currently covers 25 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageHealthcare25 companies100.0%Ashwani Verma of UBS Group specializes in stock coverage within the Healthcare sector.Coverage IndustriesIndustryPercentageBIOTECHNOLOGY13 companies52.0%PHARMACEUTICALS12 companies48.0% Ashwani Verma's Ratings History at UBS Group Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter Export CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsTEVATeva Pharmaceutical Industries9/4/2026Boost Price Target$36.47$48.00Buy$0.0000.00% ROIASMBAssembly Biosciences9/1/2026Initiated Coverage$33.63$52.00Buy$0.0000.00% ROIASMBAssembly Biosciences9/1/2026Initiated Coverage$35.18$52.00Buy$0.0000.00% ROIAXSMAxsome Therapeutics8/24/2026Reiterated Rating$207.77Buy$0.0000.00% ROIACADACADIA Pharmaceuticals8/17/2026Boost Price Target$28.24$49.00Buy$0.0000.00% ROIAXSMAxsome Therapeutics8/11/2026Initiated Coverage$220.89Market Perform$0.0000.00% ROIMPLTMaplight Therapeutics8/10/2026Downgrade$12.17$13.00Neutral$0.0000.00% ROIJAZZJazz Pharmaceuticals8/4/2026Reiterated Rating$251.58$315.00Buy$0.0000.00% ROIAMRXAmneal Pharmaceuticals8/3/2026Boost Price Target$18.58$25.00Buy$0.0000.00% ROIEXELExelixis8/3/2026Set Price Target$53.03$55.00$0.0000.00% ROI Get the Latest News and Ratings for Your StocksEnter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. CRNXCrinetics Pharmaceuticals7/28/2026Reiterated Rating$83.85$85.00Neutral$0.0000.00% ROILEGNLegend Biotech7/27/2026Reiterated Rating$18.89$28.00Neutral$0.0000.00% ROICRNXCrinetics Pharmaceuticals7/27/2026Downgrade$83.86Hold$0.0000.00% ROILEGNLegend Biotech7/24/2026Downgrade$23.53$28.00Neutral$0.0000.00% ROIMPLTMaplight Therapeutics7/21/2026Boost Price Target$35.99$52.00Buy$0.0000.00% ROIAMRXAmneal Pharmaceuticals7/15/2026Boost Price Target$17.10$23.00Buy$0.0000.00% ROIEXELExelixis7/2/2026Reiterated Rating$53.96Buy$0.0000.00% ROICRNXCrinetics Pharmaceuticals7/2/2026Initiated Coverage$38.68$55.00Buy$0.0000.00% ROIEXELExelixis7/2/2026Boost Price Target$53.96$52.00Neutral$0.0000.00% ROICYTKCytokinetics6/29/2026Upgrade$82.17$115.00Buy$0.0000.00% ROIINCYIncyte6/26/2026Boost Price Target$107.53$113.00Neutral$0.0000.00% ROILEGNLegend Biotech6/3/2026Boost Price Target$36.28$49.00Buy$0.0000.00% ROILEGNLegend Biotech6/1/2026Boost Price Target$27.16$50.00Buy$0.0000.00% ROICORTCorcept Therapeutics5/28/2026Set Price Target$66.24$135.00$0.0000.00% ROIMPLTMaplight Therapeutics5/26/2026Initiated Coverage$29.46$48.00Buy$0.0000.00% ROIMPLTMaplight Therapeutics5/26/2026Upgrade$29.78Strong-Buy$0.0000.00% ROIJAZZJazz Pharmaceuticals5/19/2026Upgrade$229.55$307.00Buy$0.0000.00% ROICORTCorcept Therapeutics5/13/2026Upgrade$51.16$72.00Buy$0.0000.00% ROIALKSAlkermes5/6/2026Boost Price Target$36.25$48.00Buy$0.0000.00% ROITEVATeva Pharmaceutical Industries4/30/2026Boost Price Target$35.03$42.00Buy$0.0000.00% ROIRPRXRoyalty Pharma4/21/2026Boost Price Target$49.30$57.00Buy$0.0000.00% ROIAMRXAmneal Pharmaceuticals4/17/2026Initiated Coverage$13.09$19.00Buy$0.0000.00% ROIAMRXAmneal Pharmaceuticals4/17/2026Initiated Coverage$13.91$19.00Buy$0.0000.00% ROIAXSMAxsome Therapeutics4/10/2026Boost Price Target$178.06$259.00Buy$0.0000.00% ROIINCYIncyte3/25/2026Lower Price Target$92.32$94.00Neutral$0.0000.00% ROIALVOAlvotech3/24/2026Lower Price Target$3.08$6.00Buy$0.0000.00% ROICYTKCytokinetics3/6/2026Boost Price Target$62.19$69.00Neutral$0.0000.00% ROIUTHRUnited Therapeutics3/5/2026Boost Price Target$487.42$705.00Buy$0.0000.00% ROIAXSMAxsome Therapeutics2/24/2026Boost Price Target$174.76$251.00Buy$0.0000.00% ROIUTHRUnited Therapeutics2/17/2026Reiterated Rating$481.56Buy$0.0000.00% ROIBuffett's Final Warning: "The Dollar Is Going to Hell" (Ad)On May 3rd, 2025, Warren Buffett looked at his shareholders for the last time and said: "The dollar is going to hell." Ray Dalio agrees. The founder of Bridgewater Associates ($150 billion AUM) calls it a "debt death spiral." But there's a specific asset class and investment system that actually thrives when the dollar collapses.Watch how to protect yourself from what Dalio and Buffett see coming (free training).HRMYHarmony Biosciences2/11/2026Downgrade$37.93$46.00Neutral$0.0000.00% ROIVTRSViatris2/9/2026Upgrade$14.58$18.00Buy$0.0000.00% ROIRPRXRoyalty Pharma1/30/2026Upgrade$40.86$49.00Buy$0.0000.00% ROINBIXNeurocrine Biosciences1/23/2026Lower Price Target$137.41$178.00Buy$0.0000.00% ROIABBVAbbVie1/7/2026Initiated Coverage$223.88$240.00Neutral$0.0000.00% ROIAXSMAxsome Therapeutics1/6/2026Boost Price Target$171.49$248.00Buy$0.0000.00% ROIACADACADIA Pharmaceuticals1/6/2026Boost Price Target$26.60$40.00Buy$0.0000.00% ROIUTHRUnited Therapeutics1/6/2026Boost Price Target$506.96$645.00Buy$0.0000.00% ROIEXELExelixis1/5/2026Set Price Target$43.58$41.00$0.0000.00% ROICORTCorcept Therapeutics12/16/2025Initiated Coverage$87.30$95.00Neutral$0.0000.00% ROICORTCorcept Therapeutics12/16/2025Initiated Coverage$82.28$95.00Hold$0.0000.00% ROILEGNLegend Biotech12/8/2025Lower Price Target$28.13$48.00Buy$0.0000.00% ROIACADACADIA Pharmaceuticals12/4/2025Reiterated Rating$26.20$35.00Buy$0.0000.00% ROICYTKCytokinetics12/1/2025Reiterated Rating$67.39$61.00Neutral$0.0000.00% ROIBHVNBiohaven11/26/2025Downgrade$9.39$11.00Neutral$0.0000.00% ROIJAZZJazz Pharmaceuticals11/24/2025Reiterated Rating$176.93$188.00Neutral$0.0000.00% ROIJAZZJazz Pharmaceuticals11/24/2025Reiterated Rating$180.90$188.00Neutral$0.0000.00% ROIALVOAlvotech11/18/2025Lower Price Target$5.11$10.00Buy$0.0000.00% ROIABBVAbbVie11/7/2025Boost Price Target$218.58$220.00Neutral$0.0000.00% ROIEXELExelixis11/6/2025Boost Price Target$40.53$40.00Neutral$0.0000.00% ROIUTHRUnited Therapeutics11/6/2025Boost Price Target$454.30$600.00Buy$0.0000.00% ROIAVDLAvadel Pharmaceuticals10/28/2025Downgrade$18.56Neutral$0.0000.00% ROIAVDLAvadel Pharmaceuticals10/28/2025Downgrade$18.56$20.00Neutral$0.0000.00% ROIHRMYHarmony Biosciences10/15/2025Lower Price Target$26.56$43.00Buy$0.0000.00% ROINBIXNeurocrine Biosciences10/9/2025Boost Price Target$139.07$195.00Buy$0.0000.00% ROIUTHRUnited Therapeutics9/29/2025Boost Price Target$432.66$580.00Buy$0.0000.00% ROITEVATeva Pharmaceutical Industries9/24/2025Boost Price Target$19.44$26.00Buy$0.0000.00% ROIBHVNBiohaven9/16/2025Lower Price Target$13.75$26.00Buy$0.0000.00% ROIACADACADIA Pharmaceuticals9/9/2025Boost Price Target$25.47$39.00Buy$00.0000.00% ROIUTHRUnited Therapeutics9/4/2025Boost Price Target$391.45$560.00Buy$000.0000.00% ROIAVDLAvadel Pharmaceuticals8/21/2025Boost Price Target$14.54$20.00Buy$0.0000.00% ROIUTHRUnited Therapeutics8/13/2025Boost Price Target$301.39$415.00Buy$000.0000.00% ROIACADACADIA Pharmaceuticals8/8/2025Boost Price Target$24.63$36.00Buy$00.0000.00% ROIEXELExelixis7/30/2025Set Price Target$37.60$38.00Neutral$00.0000.00% ROIIMVTImmunovant7/28/2025Boost Price Target$16.76$18.00Neutral$00.0000.00% ROIEXELExelixis7/11/2025Set Price Target$44.86$43.00Neutral$00.0000.00% ROINBIXNeurocrine Biosciences7/9/2025Boost Price Target$130.90$174.00Buy$000.0000.00% ROILEGNLegend Biotech7/2/2025Set Price Target$35.92$54.00Buy$00.0000.00% ROIUTHRUnited Therapeutics6/30/2025Lower Price Target$287.25$385.00Buy$000.0000.00% ROITEVATeva Pharmaceutical Industries6/26/2025Lower Price Target$17.00$23.00Buy$00.0000.00% ROINBIXNeurocrine Biosciences5/6/2025Boost Price Target$125.03$152.00Buy$000.0000.00% ROICYTKCytokinetics5/2/2025Lower Price Target$37.35$41.00Neutral$00.0000.00% ROIHRMYHarmony Biosciences4/28/2025Lower Price Target$29.36$48.00Buy$00.0000.00% ROIACADACADIA Pharmaceuticals4/28/2025Lower Price Target$14.66$22.00Buy$00.0000.00% ROICHRSCoherus Oncology4/24/2025Reiterated Rating$1.07$1.05Neutral$0.0000.00% ROINBIXNeurocrine Biosciences4/4/2025Lower Price Target$95.14$137.00Buy$000.0000.00% ROIJAZZJazz Pharmaceuticals3/7/2025Upgrade$136.45$179.00Buy$000.0000.00% ROIALKSAlkermes3/4/2025Upgrade$34.11$38.00Neutral$00.0000.00% ROINBIXNeurocrine Biosciences1/30/2025Boost Price Target$153.29$176.00Buy$000.0000.00% ROITEVATeva Pharmaceutical Industries1/30/2025Lower Price Target$17.88$27.00Buy$00.0000.00% ROISmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid (Ad)A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from collapsing — and billionaire Sam Altman is now an investor. This under-the-radar firm is drawing serious attention from those watching the energy infrastructure space closely.Click here to learn this company's name for free todayTEVATeva Pharmaceutical Industries1/23/2025Boost Price Target$22.00$30.00Buy$00.0000.00% ROIAVDLAvadel Pharmaceuticals1/13/2025Lower Price Target$7.83$14.00Buy$00.0000.00% ROI Stock Forecasts and Research Tools Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Top Stock Recommendations by BrokerageCitigroupUBS GroupBarclaysRoyal Bank Of CanadaMorgan StanleyWells Fargo & CompanyJPMorgan Chase & Co.Jefferies Financial GroupThe Goldman Sachs GroupTD CowenTruist FinancialPiper SandlerDeutsche Bank AktiengesellschaftBMO Capital MarketsMizuho Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
